Bridge to Life has received FDA De Novo clearance for its VitaSmart hypothermic oxygenated perfusion (HOPE) system for liver ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback